Gynecologic Oncology
Torl Biotherapeutics LLC focuses on clinical research in ovarian cancer, fallopian tube cancer, and peritoneal cancer, with an emphasis on advanced disease in women.
- Advanced ovarian cancer
- Fallopian tube malignancies
- Primary peritoneal cancer
The sponsor’s research activity is centered on gynecologic malignancies that share overlapping clinical features and treatment needs.
CLDN6-Targeted Oncology
The clinical program includes interest in CLDN6-expressing tumors, reflecting a therapeutic focus on biomarker-defined cancer populations.
- CLDN6 expression
- Targeted cancer therapy
- Biomarker-selected tumors
This area connects molecular tumor profiling with treatment development in solid tumors of gynecologic origin.
Monotherapy in Advanced Disease
Torl Biotherapeutics LLC is engaged in research on single-agent treatment strategies for advanced recurrent disease, particularly in patients with limited therapeutic options.
- Monotherapy
- Recurrent ovarian cancer
- Advanced cancer management
The clinical focus is on treatment settings where disease persistence and progression remain major concerns in oncology.
Multinational Clinical Development
The sponsor’s research footprint spans multiple collaborating sites across North America, Europe, and other active regions, indicating an international clinical development network.
- Multicenter oncology research
- International trial participation
- Collaborative site network
This supports access to patients with advanced gynecologic cancers across several countries.
